Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 31, 2025Hematology ReportsOpen Access

Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SIS. ItoTHTakashi HamadaMNMasaru Nakagawa

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows promise of daratumumab with dexamethasone in multiple myeloma after bortezomib failure, highlighting transplant outcomes.

Key Points

  • Overall, 50% of patients showed measurable residual disease negativity after daratumumab treatment, which is promising for myeloma management.
  • In a small salvage group, 75% achieved a very good partial response after daratumumab treatment, demonstrating its potential efficacy.
  • Patients receiving dexamethasone-based therapy had a 2-year treatment-free survival of 88%, compared to 49% in controls, offering a potential advantage after ASCT.
  • However, hypogammaglobulinemia occurred in 75% of the salvage patients, indicating a risk with this therapeutic approach.

Cite This Study

Ito et al. (2025) studied this question.

synapsesocial.com/papers/6903fee5b25c631a4265fea8https://doi.org/10.3390/hematolrep17060057
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025
  2. 2Survival and clinical response to bortezomib, thalidomide, and dexamethasone in patients with multiple myeloma at a peruvian tertiary care center: A real-world retrospective observational study2025
  3. 3Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.2025
  4. 4Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study2025
  5. 5Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025